# W Marston Linehan

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 313 papers | 32,095 citations | 89 h-index | 175 g-index |
| 332 ext. papers | 36,773 ext. citations | 7.7 avg, IF | 6.79 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 313 | Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science*, **1993**, 260, 1317-20 | 33.3 | 2363 |
| 312 | Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nature Genetics*, **1997**, 16, 68-73 | 36.3 | 1289 |
| 311 | von Hippel-Lindau disease. *Lancet, The*, **2003**, 361, 2059-67 | 40 | 1083 |
| 310 | Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 390-7 | 27.4 | 999 |
| 309 | Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature*, **2011**, 481, 385-8 | 50.4 | 853 |
| 308 | Biochemical diagnosis of pheochromocytoma: which test is best?. *JAMA - Journal of the American Medical Association*, **2002**, 287, 1427-34 | 27.4 | 792 |
| 307 | Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 135-45 | 59.2 | 753 |
| 306 | HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. *Cancer Cell*, **2005**, 8, 143-53 | 24.3 | 740 |
| 305 | Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. *Cancer Cell*, **2002**, 2, 157-64 | 24.3 | 705 |
| 304 | The somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell*, **2014**, 26, 319-330 | 24.3 | 521 |
| 303 | The genetic basis of kidney cancer: a metabolic disease. *Nature Reviews Urology*, **2010**, 7, 277-85 | 5.5 | 516 |
| 302 | Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. *American Journal of Human Genetics*, **2003**, 73, 95-106 | 11 | 479 |
| 301 | Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. *Human Mutation*, **1995**, 5, 66-75 | 4.7 | 475 |
| 300 | Renal tumors in the Birt-Hogg-Dubé syndrome. *American Journal of Surgical Pathology*, **2002**, 26, 1542-52 | 6.7 | 449 |
| 299 | Novel mutations of the MET proto-oncogene in papillary renal carcinomas. *Oncogene*, **1999**, 18, 2343-50 | 9.2 | 438 |
| 298 | Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. *Clinical Cancer Research*, **2008**, 14, 4726-34 | 12.9 | 422 |
| 297 | Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Human Mutation*, **1998**, 12, 417-23 | 4.7 | 406 |

| | | | |
|---|---|---|---|
| 296 | Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. *Annals of Internal Medicine*, **2001**, 134, 315-29 | 8 | 402 |
| 295 | The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell*, **2002**, 1, 247-55 | 24.3 | 388 |
| 294 | The genetic basis of cancer of the kidney. *Journal of Urology*, **2003**, 170, 2163-72 | 2.5 | 388 |
| 293 | Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 15552-7 | 11.5 | 367 |
| 292 | Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. *Human Mutation*, **1996**, 8, 348-57 | 4.7 | 358 |
| 291 | Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. *Journal of Clinical Oncology*, **2013**, 31, 181-6 | 2.2 | 336 |
| 290 | Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. *American Journal of Human Genetics*, **2005**, 76, 1023-33 | 11 | 304 |
| 289 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5 | 10.6 | 295 |
| 288 | Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. *American Journal of Human Genetics*, **2001**, 69, 876-82 | 11 | 285 |
| 287 | Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 175, 1044-53 | 10.2 | 256 |
| 286 | High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 4505-9 | 5.6 | 255 |
| 285 | Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. *Oncogene*, **1997**, 15, 2233-9 | 9.2 | 254 |
| 284 | Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. *Nature Genetics*, **1998**, 20, 66-9 | 36.3 | 253 |
| 283 | Hereditary papillary renal cell carcinoma. *Journal of Urology*, **1994**, 151, 561-6 | 2.5 | 235 |
| 282 | Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. *Electrophoresis*, **2000**, 21, 2235-42 | 3.6 | 232 |
| 281 | Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. *Clinical Chemistry*, **2011**, 57, 411-20 | 5.5 | 225 |
| 280 | Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 1999-2008 | 5.6 | 224 |
| 279 | Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. *Journal of Urology*, **2005**, 173, 1482-6 | 2.5 | 221 |

| | | | |
|---|---|---|---|
| 278 | Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. *Cell Reports*, **2014**, 7, 1679-1690 | 10.6 | 216 |
| 277 | Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. *Journal of Urology*, **1999**, 162, 659-64 | 2.5 | 207 |
| 276 | Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. *Journal of Urology*, **2012**, 188, 2152-2157 | 2.5 | 199 |
| 275 | Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. *American Journal of Pathology*, **1998**, 153, 223-31 | 5.8 | 199 |
| 274 | Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. *American Journal of Pathology*, **1999**, 155, 517-26 | 5.8 | 199 |
| 273 | Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). *Surgery*, **2007**, 142, 814-8; discussion 818.e1-2 | 3.6 | 196 |
| 272 | Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. *Journal of the National Cancer Institute*, **2008**, 100, 140-54 | 9.7 | 194 |
| 271 | Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. *Journal of Urology*, **2007**, 177, 2074-9; discussion 2079-80 | 2.5 | 191 |
| 270 | Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. *Journal of Urology*, **1999**, 161, 1475-9 | 2.5 | 189 |
| 269 | Robotic partial nephrectomy for complex renal tumors: surgical technique. *European Urology*, **2008**, 53, 514-21 | 10.2 | 187 |
| 268 | Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 18722-7 | 11.5 | 184 |
| 267 | High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. *Journal of the National Cancer Institute*, **2005**, 97, 931-5 | 9.7 | 184 |
| 266 | Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. *Molecular and Cellular Biology*, **2009**, 29, 4080-90 | 4.8 | 181 |
| 265 | Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. *Journal of Urology*, **2012**, 188, 2063-71 | 2.5 | 175 |
| 264 | Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. *Cell*, **2019**, 179, 964-983.e31 | 31.2 | 173 |
| 263 | Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. *Familial Cancer*, **2014**, 13, 637-44 | 3 | 170 |
| 262 | Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. *Nature Reviews Urology*, **2014**, 11, 465-75 | 5.5 | 169 |
| 261 | Hereditary renal cancers. *Radiology*, **2003**, 226, 33-46 | 20.5 | 164 |

| | | | |
|---|---|---|---|
| 260 | Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. *Genome Research*, **2012**, 22, 2089-100 | 9.7 | 162 |
| 259 | Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dub syndrome. *Cancer Epidemiology Biomarkers and Prevention*, **2002**, 11, 393-400 | 4 | 162 |
| 258 | The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. *Nature Reviews Urology*, **2019**, 16, 539-552 | 5.5 | 160 |
| 257 | Genetic basis of cancer of the kidney: disease-specific approaches to therapy. *Clinical Cancer Research*, **2004**, 10, 6282S-9S | 12.9 | 159 |
| 256 | PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. *Journal of Urology*, **2001**, 165, 777-781 | 2.5 | 159 |
| 255 | The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. *Journal of Urology*, **2004**, 172, 63-5 | 2.5 | 156 |
| 254 | Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. *Journal of Urology*, **1995**, 153, 907-912 | 2.5 | 154 |
| 253 | Correlation of magnetic resonance imaging tumor volume with histopathology. *Journal of Urology*, **2012**, 188, 1157-1163 | 2.5 | 152 |
| 252 | The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. *Cancer Cell*, **2011**, 20, 315-27 | 24.3 | 152 |
| 251 | Identification and characterization of a novel folliculin-interacting protein FNIP2. *Gene*, **2008**, 415, 60-7 | 3.8 | 143 |
| 250 | Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. *Journal of Urology*, **1995**, 154, 2010-2015 | 2.5 | 142 |
| 249 | LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. *Journal of Urology*, **2001**, 166, 68-72 | 2.5 | 141 |
| 248 | Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. *PLoS Genetics*, **2011**, 7, e1002312 | 6 | 140 |
| 247 | Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. *Clinical Cancer Research*, **2013**, 19, 3345-52 | 12.9 | 139 |
| 246 | Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. *Oncologist*, **2012**, 17, 46-54 | 5.7 | 139 |
| 245 | Molecular diagnosis and therapy of kidney cancer. *Annual Review of Medicine*, **2010**, 61, 329-43 | 17.4 | 135 |
| 244 | Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. *Journal of Urology*, **2008**, 180, 2353-6; discussion 2356 | 2.5 | 131 |
| 243 | Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. *Endocrine-Related Cancer*, **2011**, 18, 97-111 | 5.7 | 127 |

| | | | |
|---|---|---|---|
| 242 | Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. *Journal of Urology*, **1995**, 153, 22-6 | 2.5 | 122 |
| 241 | Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. *Drug Development Research*, **2000**, 49, 34-42 | 5.1 | 120 |
| 240 | Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome. *Nature Reviews Urology*, **2015**, 12, 558-69 | 5.5 | 116 |
| 239 | Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. *Clinical Cancer Research*, **2007**, 13, 671s-679s | 12.9 | 113 |
| 238 | UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. *Cancer Genetics and Cytogenetics*, **2010**, 196, 45-55 | | 112 |
| 237 | A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. *Molecular Cancer Research*, **2013**, 11, 1061-1071 | 6.6 | 111 |
| 236 | Familial renal oncocytoma: clinicopathological study of 5 families. *Journal of Urology*, **1998**, 160, 335-40 | 2.5 | 108 |
| 235 | Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. *Modern Pathology*, **2004**, 17, 998-1011 | 9.8 | 106 |
| 234 | Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. *Journal of Urology*, **1997**, 158, 1675-8 | 2.5 | 105 |
| 233 | Focus on kidney cancer. *Cancer Cell*, **2004**, 6, 223-8 | 24.3 | 105 |
| 232 | Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. *Journal of Urology*, **1993**, 150, 463-6 | 2.5 | 104 |
| 231 | Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. *PLoS ONE*, **2010**, 5, e15793 | 3.7 | 103 |
| 230 | Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. *Oncogene*, **1999**, 18, 1205-8 | 9.2 | 101 |
| 229 | The metabolic basis of kidney cancer. *Seminars in Cancer Biology*, **2013**, 23, 46-55 | 12.7 | 100 |
| 228 | Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. *American Journal of Surgical Pathology*, **2010**, 34, 757-66 | 6.7 | 96 |
| 227 | Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. *Journal of Clinical Oncology*, **2014**, 32, 431-7 | 2.2 | 95 |
| 226 | Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. *Journal of Urology*, **1999**, 162, 43-5 | 2.5 | 92 |
| 225 | Hereditary kidney cancer: unique opportunity for disease-based therapy. *Cancer*, **2009**, 115, 2252-61 | 6.4 | 89 |

| | | | |
|---|---|---|---|
| 224 | Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. *Journal of Urology*, **2004**, 172, 1256-61 | 2.5 | 88 |
| 223 | Hereditary leiomyomatosis and renal cell carcinoma. *International Journal of Nephrology and Renovascular Disease*, **2014**, 7, 253-60 | 2.5 | 86 |
| 222 | Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. *Journal of Urology*, **1995**, 153, 913-916 | 2.5 | 80 |
| 221 | Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. *Journal of Urology*, **1990**, 144, 614-7; discussion 617-8 | 2.5 | 80 |
| 220 | Translocation renal cell carcinomas in adults: a single-institution experience. *American Journal of Surgical Pathology*, **2012**, 36, 654-62 | 6.7 | 79 |
| 219 | MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. *Journal of Urology*, **1999**, 161, 395-398 | 2.5 | 79 |
| 218 | Surgical management of pheochromocytoma with the use of metyrosine. *Annals of Surgery*, **1990**, 212, 621-8 | 7.8 | 79 |
| 217 | Epididymal cystadenomas in von Hippel-Lindau disease. *Urology*, **1997**, 49, 926-31 | 1.6 | 78 |
| 216 | Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. *Human Mutation*, **2004**, 23, 40-6 | 4.7 | 78 |
| 215 | Genetic predisposition to kidney cancer. *Seminars in Oncology*, **2016**, 43, 566-574 | 5.5 | 77 |
| 214 | PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. *Journal of Urology*, **2000**, 163, 431-433 | 2.5 | 76 |
| 213 | New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease. *Clinical Cancer Research*, **2015**, 21, 10-7 | 12.9 | 75 |
| 212 | SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. *Journal of the National Cancer Institute*, **2016**, 108, | 9.7 | 73 |
| 211 | Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. *Molecular Cancer*, **2010**, 9, 160 | 42.1 | 71 |
| 210 | Partial adrenalectomy: the National Cancer Institute experience. *Urology*, **2005**, 66, 19-23 | 1.6 | 71 |
| 209 | Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. *PLoS ONE*, **2013**, 8, e72179 | 3.7 | 71 |
| 208 | Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. *Cell Reports*, **2014**, 7, 412-423 | 10.6 | 70 |
| 207 | Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. *Journal of the National Cancer Institute*, **2012**, 104, 1750-64 | 9.7 | 70 |

| | | | |
|---|---|---|---|
| 206 | EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEOBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. *Journal of Urology*, **2001**, 165, 1329-1334 | 2.5 | 70 |
| 205 | The Metabolic Basis of Kidney Cancer. *Cancer Discovery*, **2019**, 9, 1006-1021 | 24.4 | 68 |
| 204 | Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. *Cancer Cell*, **2014**, 26, 840-850 | 24.3 | 67 |
| 203 | FLCN: The causative gene for Birt-Hogg-Dub□syndrome. *Gene*, **2018**, 640, 28-42 | 3.8 | 66 |
| 202 | Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. *Journal of Urology*, **2013**, 190, 1990-8 | 2.5 | 66 |
| 201 | Diagnosis and management of BHD-associated kidney cancer. *Familial Cancer*, **2013**, 12, 397-402 | 3 | 65 |
| 200 | Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. *Archives of Dermatology*, **2008**, 144, 1584-92 | | 65 |
| 199 | Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. *Journal of Cancer*, **2011**, 2, 515-26 | 4.5 | 64 |
| 198 | Endolymphatic sac tumors in von Hippel-Lindau disease. *Journal of Neurosurgery*, **2004**, 100, 480-7 | 3.2 | 64 |
| 197 | Englerin A stimulates PKC□to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. *Cancer Cell*, **2013**, 23, 228-37 | 24.3 | 61 |
| 196 | Targeting the Met signaling pathway in renal cancer. *Expert Review of Anticancer Therapy*, **2009**, 9, 785-93 | 3.5 | 60 |
| 195 | Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1624-31 | 11.5 | 59 |
| 194 | Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. *Journal of Urology*, **2008**, 179, 67-70 | 2.5 | 59 |
| 193 | Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. *Journal of Urology*, **2010**, 184, 1855-9 | 2.5 | 58 |
| 192 | Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. *JAMA Ophthalmology*, **2007**, 125, 239-45 | | 58 |
| 191 | Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. *Cancer Research*, **2016**, 76, 2177-85 | 10.1 | 56 |
| 190 | Imaging features of hereditary papillary renal cancers. *Journal of Computer Assisted Tomography*, **1997**, 21, 737-41 | 2.2 | 55 |
| 189 | Metabolism of kidney cancer: from the lab to clinical practice. *European Urology*, **2013**, 63, 244-51 | 10.2 | 54 |

| | | | |
|---|---|---|---|
| 188 | Studying cancer families to identify kidney cancer genes. *Annual Review of Medicine*, **2003**, 54, 217-33 | 17.4 | 54 |
| 187 | Development of a prostate cDNA microarray and statistical gene expression analysis package **2000**, 28, 12-22 | | 54 |
| 186 | Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. *Hepatology*, **2015**, 62, 1122-31 | 11.2 | 53 |
| 185 | The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dub□syndrome is required for murine B-cell development. *Blood*, **2012**, 120, 1254-61 | 2.2 | 52 |
| 184 | Initial experience with robot assisted partial nephrectomy for multiple renal masses. *Journal of Urology*, **2009**, 182, 1280-6 | 2.5 | 52 |
| 183 | Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling. *Cell Chemical Biology*, **2017**, 24, 231-242 | 8.2 | 50 |
| 182 | Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique. *European Urology*, **2011**, 60, 118-24 | 10.2 | 49 |
| 181 | A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. *Cancer Genetics*, **2012**, 205, 377-90 | 2.3 | 47 |
| 180 | Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. *Cancer*, **2002**, 94, 690-9 | 6.4 | 47 |
| 179 | ONC201 kills breast cancer cells by targeting mitochondria. *Oncotarget*, **2018**, 9, 18454-18479 | 3.3 | 45 |
| 178 | Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. *Clinical Cancer Research*, **2018**, 24, 5977-5989 | 12.9 | 44 |
| 177 | Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. *Human Molecular Genetics*, **2014**, 23, 5706-19 | 5.6 | 44 |
| 176 | Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dub□ syndrome. *Genes Chromosomes and Cancer*, **2011**, 50, 466-77 | 5 | 44 |
| 175 | Acute loss of iron-sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. *Journal of Biological Chemistry*, **2018**, 293, 8297-8311 | 5.4 | 43 |
| 174 | VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. *International Journal of Biochemistry and Cell Biology*, **2009**, 41, 753-6 | 5.6 | 43 |
| 173 | The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dub□gene pathway. *Cancer Genetics and Cytogenetics*, **2008**, 180, 100-9 | | 43 |
| 172 | Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. *PLoS ONE*, **2014**, 9, e85621 | 3.7 | 43 |
| 171 | Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. *European Urology*, **2019**, 76, 754-764 | 10.2 | 42 |

| | | | |
|---|---|---|---|
| 170 | Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). *PLoS ONE*, **2015**, 10, e0140257 | 3.7 | 42 |
| 169 | Robot-assisted laparoscopic partial adrenalectomy: initial experience. *Urology*, **2011**, 77, 775-80 | 1.6 | 41 |
| 168 | Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. *Expert Opinion on Biological Therapy*, **2008**, 8, 779-90 | 5.4 | 41 |
| 167 | Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. *Genes Chromosomes and Cancer*, **1995**, 13, 151-6 | 5 | 41 |
| 166 | The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. *BJU International*, **2005**, 95 Suppl 2, 2-7 | 5.6 | 39 |
| 165 | Superiority of Ga-DOTATATE over F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 787-797 | 8.8 | 38 |
| 164 | The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. *Nature Communications*, **2016**, 7, 12037 | 17.4 | 37 |
| 163 | A chemoproteomic portrait of the oncometabolite fumarate. *Nature Chemical Biology*, **2019**, 15, 391-400 | 11.7 | 37 |
| 162 | Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome. *Expert Opinion on Orphan Drugs*, **2015**, 3, 15-29 | 1.1 | 35 |
| 161 | Evaluation of color Doppler intraoperative ultrasound in parenchymal sparing renal surgery. *Journal of Urology*, **1994**, 152, 1984-7 | 2.5 | 35 |
| 160 | Management of von Hippel-Lindau-associated kidney cancer. *Nature Reviews Urology*, **2005**, 2, 248-55 | | 34 |
| 159 | The genetic basis of pheochromocytoma and paraganglioma: implications for management. *Urology* , **2014**, 83, 1225-32 | 1.6 | 33 |
| 158 | Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. *Cell Reports*, **2020**, 30, 1798-1810.e4 | 10.6 | 32 |
| 157 | Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. *Seminars in Oncology*, **2013**, 40, 511-20 | 5.5 | 31 |
| 156 | Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma. *Clinical Cancer Research*, **2013**, 19, 42-9 | 12.9 | 31 |
| 155 | Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. *Genes Chromosomes and Cancer*, **1994**, 11, 15-20 | 5 | 31 |
| 154 | MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. *Cancer Science*, **2019**, 110, 1897-1908 | 6.9 | 30 |
| 153 | Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. *JAMA Oncology*, **2018**, 4, 124-126 | 13.4 | 30 |

| | | | |
|---|---|---|---|
| 152 | PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study. *Abdominal Radiology*, **2016**, 41, 109-18 | 3 | 29 |
| 151 | Kidney cancer. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 948-51 | 2.8 | 28 |
| 150 | A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. *Journal of Urology*, **1991**, 145, 1040-2 | 2.5 | 28 |
| 149 | Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, 1-6 | 3.3 | 28 |
| 148 | Recommendations for the Management of Rare Kidney Cancers. *European Urology*, **2017**, 72, 974-983 | 10.2 | 27 |
| 147 | Targeted therapies for non-clear renal cell carcinoma. *Targeted Oncology*, **2010**, 5, 119-29 | 5 | 27 |
| 146 | Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. *Science*, **2021**, 373, 236-241 | 33.3 | 26 |
| 145 | SnapShot: Renal Cell Carcinoma. *Cancer Cell*, **2016**, 29, 610-610.e1 | 24.3 | 26 |
| 144 | Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. *Nature Communications*, **2021**, 12, 808 | 17.4 | 26 |
| 143 | Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. *Cell Cycle*, **2010**, 9, 4183-9 | 4.7 | 25 |
| 142 | A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. *Journal of Translational Medicine*, **2010**, 8, 8 | 8.5 | 25 |
| 141 | Phase II study of the oral HIF-2 inhibitor MK-6482 for Von Hippel-Lindau disease associated renal cell carcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 5003-5003 | 2.2 | 25 |
| 140 | Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. *Journal of Clinical Oncology*, **2020**, 38, 5004-5004 | 2.2 | 25 |
| 139 | Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. *American Journal of Human Genetics*, **2018**, 103, 358-366 | 11 | 24 |
| 138 | Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. *Cell Reports*, **2019**, 26, 1344-1356.e5 | 10.6 | 23 |
| 137 | Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. *Cell*, **2018**, 173, 540-542 | 56.2 | 23 |
| 136 | Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. *Journal of Neurosurgery*, **2016**, 124, 971-6 | 3.2 | 23 |
| 135 | Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. *Urology*, **1997**, 50, 295-301 | 1.6 | 22 |

| | | | |
|---|---|---|---|
| 134 | Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression. *Journal of Biomolecular Screening*, **2006**, 11, 678-87 | | 22 |
| 133 | Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. *Journal of Clinical Oncology*, **2020**, 38, 1146-1153 | 2.2 | 21 |
| 132 | Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. *Cancer*, **2009**, 115, 2247-51 | 6.4 | 21 |
| 131 | Fine-needle aspiration of metastatic clear cell carcinoma of the kidney. *Cancer*, **1997**, 81, 180-186 | 6.4 | 21 |
| 130 | Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. *Stem Cells*, **2016**, 34, 1068-82 | 5.8 | 21 |
| 129 | Targeting HIF2□n Clear-Cell Renal Cell Carcinoma. *Cancer Cell*, **2016**, 30, 515-517 | 24.3 | 21 |
| 128 | Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. *Science Signaling*, **2021**, 14, | 8.8 | 21 |
| 127 | Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 23.e9-13 | 2.8 | 20 |
| 126 | Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. *Journal of Clinical Oncology*, **2018**, JCO2018792309 | 2.2 | 20 |
| 125 | Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dub□tumors. *Modern Pathology*, **2015**, 28, 1458-69 | 9.8 | 19 |
| 124 | Decade in review-kidney cancer: discoveries, therapies and opportunities. *Nature Reviews Urology*, **2014**, 11, 614-6 | 5.5 | 19 |
| 123 | Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome. *JAMA Dermatology*, **2015**, 151, 770-4 | 5.1 | 19 |
| 122 | Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[ 18 F]Fluorodopamine Positron Emission Tomography. *Journal of Urology*, **2003**, 169, 274-275 | 2.5 | 19 |
| 121 | Targeting HIF2□translation with Tempol in VHL-deficient clear cell renal cell carcinoma. *Oncotarget*, **2012**, 3, 1472-82 | 3.3 | 19 |
| 120 | Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. *Nature Communications*, **2016**, 7, 11588 | 17.4 | 19 |
| 119 | Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 167.e13-20 | 2.8 | 18 |
| 118 | Familial renal cancer: molecular genetics and surgical management. *International Journal of Surgical Oncology*, **2011**, 2011, 658767 | 0.9 | 18 |
| 117 | Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: utilization of microdissection and polymerase chain reaction in archival tissues. *Diagnostic Cytopathology*, **2001**, 24, 328-32 | 1.4 | 18 |

| | | | |
|---|---|---|---|
| 116 | The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. *Prostate*, **1987**, 10, 189-97 | 4.2 | 18 |
| 115 | Targeting loss of the Hippo signaling pathway in -deficient papillary kidney cancers. *Oncotarget*, **2018**, 9, 10723-10733 | 3.3 | 18 |
| 114 | Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. *Genes Chromosomes and Cancer*, **2017**, 56, 484-492 | 5 | 17 |
| 113 | Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. *Journal of the American Chemical Society*, **2016**, 138, 15813-15816 | 16.4 | 17 |
| 112 | Impact of genetics on the diagnosis and treatment of renal cancer. *Current Urology Reports*, **2011**, 12, 47-55 | 2.9 | 17 |
| 111 | A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. *Cancer*, **1992**, 69, 213-8 | 6.4 | 17 |
| 110 | Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan **1996**, 8, 348 | | 17 |
| 109 | Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2□nduced gene expression. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2113-5 | 2.9 | 16 |
| 108 | A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. *Journal of Urology*, **2003**, 169, 357-360 | 2.5 | 16 |
| 107 | Genetic basis of bilateral renal cancer: implications for evaluation and management. *Journal of Clinical Oncology*, **2009**, 27, 3731-3 | 2.2 | 15 |
| 106 | H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation. *Human Molecular Genetics*, **2017**, 26, 354-366 | 5.6 | 15 |
| 105 | Targeting VEGF receptors in kidney cancer. *Lancet Oncology, The*, **2007**, 8, 956-7 | 21.7 | 14 |
| 104 | Multiple painful cutaneous nodules and renal mass. *Journal of the American Academy of Dermatology*, **2006**, 55, 683-6 | 4.5 | 14 |
| 103 | Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers. *Journal of Urology*, **2004**, 172, 49-53 | 2.5 | 14 |
| 102 | Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease. *Cancer*, **2019**, 125, 1060-1069 | 6.4 | 14 |
| 101 | Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. *Blood*, **2021**, 137, 126-137 | 2.2 | 14 |
| 100 | Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial. *JAMA Dermatology*, **2015**, 151, 1096-102 | 5.1 | 13 |
| 99 | Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. *International Urology and Nephrology*, **2016**, 48, 1817-1821 | 2.3 | 13 |

| | | | |
|---|---|---|---|
| 98 | Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. *Journal of the American College of Surgeons*, **2014**, 218, 997-1003 | 4.4 | 13 |
| 97 | Hypoxia-Inducible Factor 2Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. *Neoplasia*, **2016**, 18, 567-76 | 6.4 | 13 |
| 96 | TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. *Molecular Cancer Research*, **2019**, 17, 1613-1626 | 6.6 | 12 |
| 95 | Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. *Journal of Natural Products*, **2012**, 75, 1632-6 | 4.9 | 12 |
| 94 | Tonantzitlolone cytotoxicity toward renal cancer cells is PKCand HSF1-dependent. *Oncotarget*, **2015**, 6, 29963-74 | 3.3 | 12 |
| 93 | Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. *ELife*, **2019**, 8, | 8.9 | 12 |
| 92 | Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene **1998**, 12, 417 | | 12 |
| 91 | Partial adrenalectomy in patients with multiple adrenal tumors. *Current Urology Reports*, **2001**, 2, 19-23 | 2.9 | 11 |
| 90 | A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. *Cell Reports*, **2020**, 30, 1823-1834.e5 | 10.6 | 11 |
| 89 | Photoinducible Oncometabolite Detection. *ChemBioChem*, **2019**, 20, 360-365 | 3.8 | 11 |
| 88 | Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics. *Nature Reviews Urology*, **2017**, 14, 76-78 | 5.5 | 10 |
| 87 | Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology **1999**, 87, 231-237 | | 10 |
| 86 | Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. *Oncotarget*, **2017**, 8, 17628-17642 | 3.3 | 10 |
| 85 | Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. *Journal of Endourology*, **2016**, 30, 1219-1226 | 2.7 | 10 |
| 84 | Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. *Urology*, **2021**, 149, 89-97 | 1.6 | 10 |
| 83 | In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1631-1638 | 5.6 | 9 |
| 82 | PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. *Journal of Urology*, **1998**, 159, 1148-1151 | 2.5 | 9 |
| 81 | Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. *Academic Radiology*, **2021**, 28, 1491-1499 | 4.3 | 9 |

| | | | |
|---|---|---|---|
| 80 | Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. *European Urology Oncology*, **2021**, | 6.7 | 9 |
| 79 | CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. *Urology*, **2019**, 124, 91-97 | 1.6 | 9 |
| 78 | Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. *Cancer Research*, **2018**, 78, 6539-6548 | 10.1 | 9 |
| 77 | Metabolic Labeling of Cultured Mammalian Cells for Stable Isotope-Resolved Metabolomics: Practical Aspects of Tissue Culture and Sample Extraction. *Methods in Molecular Biology*, **2019**, 1928, 1-27 | 1.4 | 8 |
| 76 | Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). *Genes Chromosomes and Cancer*, **2017**, 56, 719-729 | 5 | 8 |
| 75 | Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. *Cancer Discovery*, **2017**, 7, 1221-1223 | 24.4 | 7 |
| 74 | Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. *Urology*, **2020**, 140, 85-90 | 1.6 | 7 |
| 73 | Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 27.e15-21 | 2.8 | 7 |
| 72 | Pulmonary infarcts can mimic pulmonary metastases from renal cancer. *Journal of Urology*, **1997**, 158, 1688-90 | 2.5 | 7 |
| 71 | PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. *Journal of Urology*, **2001**, 165, 1623-1624 | 2.5 | 7 |
| 70 | Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. *World Journal of Urology*, **1996**, 14 Suppl 1, S2-7 | 4 | 7 |
| 69 | Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. *International Urology and Nephrology*, **2016**, 48, 1047-1053 | 2.3 | 6 |
| 68 | Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. *Pharmaceutical Research*, **2016**, 33, 2459-69 | 4.5 | 6 |
| 67 | A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. *Clinical Cancer Research*, **2019**, 25, 6302-6308 | 12.9 | 6 |
| 66 | Therapeutic inhibition of HIF-2 reverses polycythemia and pulmonary hypertension in murine models of human diseases. *Blood*, **2021**, 137, 2509-2519 | 2.2 | 6 |
| 65 | BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. *Human Molecular Genetics*, **2018**, 27, 2712-2724 | 5.6 | 6 |
| 64 | Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines **2000**, 21, 2235 | | 6 |
| 63 | Birt-Hogg-Dub syndrome initially diagnosed as tuberous sclerosis complex. *JAAD Case Reports*, **2019**, 5, 368-371 | 1.4 | 5 |

| | | | |
|---|---|---|---|
| 62 | Blood and lymphatic systems are segregated by the FLCN tumor suppressor. *Nature Communications*, **2020**, 11, 6314 | 17.4 | 5 |
| 61 | Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. *Journal of Cancer*, **2020**, 11, 3596-3603 | 4.5 | 5 |
| 60 | The origin, evolution and route to metastasis of clear cell RCC. *Nature Reviews Nephrology*, **2018**, 14, 538-540 | 14.9 | 5 |
| 59 | Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc. *Scientific Reports*, **2019**, 9, 18409 | 4.9 | 5 |
| 58 | Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. *Journal of Clinical Investigation*, **2021**, 131, | 15.9 | 5 |
| 57 | Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. *Clinical Imaging*, **2020**, 68, 14-19 | 2.7 | 4 |
| 56 | Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 344-352 | 4 | 4 |
| 55 | Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect.. *JCO Precision Oncology*, **2017**, 1, 1-14 | 3.6 | 4 |
| 54 | Looking forward, looking back-10 years in urology. *Nature Reviews Urology*, **2014**, 11, 649-55 | 5.5 | 4 |
| 53 | Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis. *Journal of Cancer*, **2011**, 2, 271-9 | 4.5 | 4 |
| 52 | Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. *Breast Journal* , **1998**, 4, 9-12 | 1.2 | 4 |
| 51 | Kidney cancer: opportunity for disease specific targeted therapy. *Urologic Oncology: Seminars and Original Investigations*, **2008**, 26, 542 | 2.8 | 4 |
| 50 | A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. *Clinical Imaging*, **2021**, 77, 291-298 | 2.7 | 4 |
| 49 | The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. *Nature Structural and Molecular Biology*, **2021**, 28, 662-670 | 17.6 | 4 |
| 48 | Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. *Journal of Clinical Oncology*, **2016**, 34, e76-9 | 2.2 | 3 |
| 47 | Metabolism and oxidative stress response pathways in kidney cancer: a tale of chance and necessity. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, 220-5 | 7.1 | 3 |
| 46 | Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. *Journal of Surgical Oncology*, **1993**, 53, 252-5 | 2.8 | 3 |
| 45 | Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 4584-4584 | 2.2 | 3 |

| | | | |
|---|---|---|---|
| 44 | Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. *Genes and Development*, **2019**, 33, 1641-1656 | 12.6 | 3 |
| 43 | Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors. *Radiology*, **2019**, 290, 116-124 | 20.5 | 3 |
| 42 | Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. *Genes*, **2021**, 12, | 4.2 | 3 |
| 41 | Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 383-383 | 2.2 | 2 |
| 40 | Treatment of Advanced Renal Cell Carcinoma **2012**, 1475-1491.e5 | | 2 |
| 39 | FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. *Biochemical and Biophysical Research Communications*, **2020**, 522, 931-938 | 3.4 | 2 |
| 38 | A germline 1;3 translocation disrupting the gene: a novel genetic cause for von Hippel-Lindau. *Journal of Medical Genetics*, **2020**, | 5.8 | 2 |
| 37 | Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. *Genes Chromosomes and Cancer*, **2020**, 59, 472-483 | 5 | 2 |
| 36 | Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease. *Radiology*, **2020**, 295, 583-590 | 20.5 | 2 |
| 35 | Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 134.e1-134.e8 | 2.8 | 2 |
| 34 | The Warburg effect in hominis: isotope-resolved metabolism in ccRCC. *Nature Reviews Urology*, **2018**, 15, 731-732 | 5.5 | 2 |
| 33 | Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip **2000**, 49, 34 | | 2 |
| 32 | Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines **2000**, 21, 2235 | | 2 |
| 31 | The Metabolic Basis of Kidney Cancer **2015**, 89-102 | | 1 |
| 30 | Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. *Urology Case Reports*, **2019**, 27, 100922 | 0.5 | 1 |
| 29 | Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline Mutation. *Urology Case Reports*, **2017**, 13, 107-109 | 0.5 | 1 |
| 28 | A mouse model of renal cell carcinoma. *Nature Medicine*, **2017**, 23, 802-803 | 50.5 | 1 |
| 27 | Seventh BHD international symposium: recent scientific and clinical advancement.. *Oncotarget*, **2022**, 13, 173-181 | 3.3 | 1 |

| | | | |
|---|---|---|---|
| 26 | Defining early-onset kidney cancer: Implications for genetic counseling.. *Journal of Clinical Oncology* , **2013**, 31, 342-342 | 2.2 | 1 |
| 25 | Hereditary Renal Cell Carcinoma **2017**, 19-82 | | 1 |
| 24 | Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF‐cytotoxicity | | 1 |
| 23 | Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite. *Journal of Biological Chemistry*, **2020**, 295, 13410-13418 | 5.4 | 1 |
| 22 | Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. *Cancer & Metabolism*, **2020**, 8, 7 | 5.4 | 1 |
| 21 | Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. *Abdominal Radiology*, **2021**, 46, 3301-3308 | 3 | 1 |
| 20 | Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. *Human Mutation*, **2021**, 42, 520-529 | 4.7 | 1 |
| 19 | Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. *Genes Chromosomes and Cancer*, **2021**, 60, 434-446 | 5 | 1 |
| 18 | Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2‐Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. *European Urology*, **2019**, 75, 882-884 | 10.2 | 1 |
| 17 | MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. *Journal of Cancer*, **2021**, 12, 5375-5384 | 4.5 | 1 |
| 16 | Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. *Cancer*, **2021**, 127, 3957-3966 | 6.4 | 1 |
| 15 | Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial. *Clinical and Experimental Ophthalmology*, **2021**, 49, 1048-1059 | 2.4 | 1 |
| 14 | An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification. *ACS Chemical Biology*, **2020**, 15, 856-861 | 4.9 | 0 |
| 13 | MPA software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.. *Cell Reports Methods*, **2022**, 2, 100136 | | 0 |
| 12 | X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. *Urology*, **2021**, 154, 315-319 | 1.6 | 0 |
| 11 | Reoperative Partial Nephrectomy-Does Previous Surgical Footprint Impact Outcomes?. *Journal of Urology*, **2021**, 206, 539-547 | 2.5 | 0 |
| 10 | A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. *Cancers*, **2022**, 14, 2643 | 6.6 | 0 |
| 9 | Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. *Urology Case Reports*, **2017**, 13, 101-103 | 0.5 | |

# List of Publications

| | | |
|---|---|---|
| 8 | Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. *Clinical Genitourinary Cancer*, **2019**, 17, e482-e484 | 3.3 |
| 7 | Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. *Urology Case Reports*, **2020**, 30, 101135 | 0.5 |
| 6 | Identification of the genes for kidney cancer. *Cancer Biology and Therapy*, **2006**, 5, 696-9 | 4.6 |
| 5 | Aids Case for Diagnosis, 1986 Military Medicine. *Military Medicine*, **1986**, 151, M49-M56 | 1.3 |
| 4 | Protein expression profiling in the spectrum of renal tumors. *FASEB Journal*, **2007**, 21, A181 | 0.9 |
| 3 | Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. *Journal of Clinical Oncology*, **2013**, 31, 307-307 | 2.2 |
| 2 | Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. *Urology Case Reports*, **2021**, 37, 101603 | 0.5 |
| 1 | Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers.. *IScience*, **2022**, 104463 | 6.1 |